Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Work In Process (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Work In Process data on record, last reported at $11.6 million in Q3 2025.

  • For Q3 2025, Work In Process fell 33.12% year-over-year to $11.6 million; the TTM value through Sep 2025 reached $11.6 million, down 33.12%, while the annual FY2024 figure was $13.2 million, 95.3% up from the prior year.
  • Work In Process reached $11.6 million in Q3 2025 per COLL's latest filing, down from $12.1 million in the prior quarter.
  • Across five years, Work In Process topped out at $46.4 million in Q2 2022 and bottomed at $802000.0 in Q1 2021.
  • Average Work In Process over 5 years is $14.1 million, with a median of $11.6 million recorded in 2025.
  • Peak YoY movement for Work In Process: soared 4252.49% in 2022, then tumbled 83.92% in 2023.
  • A 5-year view of Work In Process shows it stood at $1.0 million in 2021, then soared by 2350.05% to $24.7 million in 2022, then tumbled by 72.68% to $6.7 million in 2023, then soared by 95.3% to $13.2 million in 2024, then decreased by 11.65% to $11.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Work In Process were $11.6 million in Q3 2025, $12.1 million in Q2 2025, and $11.6 million in Q1 2025.